Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8579255 | PMC |
| http://dx.doi.org/10.1182/bloodadvances.2021005637 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Letermovir prophylaxis for cytomegalovirus in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation.
Bone Marrow Transplant
January 2025
Department of Hematology and Oncology, Children's Hospital of Soochow University, Suzhou, China.
Optimized GVHD Prevention in HLA-Mismatched Unrelated Allogeneic HCT Using a PTCY-Based Approach.
Eur J Haematol
December 2024
Hematopoietic Transplantation Unit, Hematology Department, Clinical Institute of Hematology and Oncology (ICMHO), Hospital Clínic de Barcelona, Barcelona, Spain.
Although post-transplant cyclophosphamide (PTCY)-based prophylaxis has become a widely adopted strategy for preventing graft-versus-host disease (GVHD) in 9 out of 10 HLA-mismatched unrelated donors (MMUDs), allogeneic hematopoietic cell transplants (allo-HCTs), data on the safety and efficacy of PTCY in this setting remain limited. This single-center study investigates the outcomes of 94 adults with hematological malignancies undergoing MMUD allo-HCT with PTCY and tacrolimus (Tac) (PTCY-Tac) between 2014 and 2023. The median age was 53 years, and 60.
View Article and Find Full Text PDFLetermovir for Prevention of Recurrent Cytomegalovirus in High-Risk Allogeneic Hematopoietic Cell Transplantation Recipients.
Transplant Cell Ther
December 2024
Infectious Diseases Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address:
We evaluated letermovir (LTV) for secondary prophylaxis for cytomegalovirus (CMV) in allogeneic hematopoietic cell transplant recipients (HCT) at high-risk for CMV recurrence. This open-label study was conducted at Memorial Sloan Kettering Cancer Center and the University of Minnesota. Patients with clinically significant CMV infection (cs-CMVi) and ≥1 high-risk criteria for CMV who achieved viral suppression with standard CMV antivirals received LTV secondary prophylaxis for up to 14 weeks.
View Article and Find Full Text PDFEffectiveness of letermovir in preventing cytomegalovirus reactivation after cord blood transplantation.
J Infect Chemother
December 2024
Department of Hematology/Oncology, Kurashiki Central Hospital, 1-1-1 Miwa, Kurashiki, 710-8602, Japan.
Article Synopsis
- Cord blood transplantation (CBT) has a high risk of cytomegalovirus (CMV) infection, and Letermovir (LTV) is an effective drug for preventing CMV reactivation after CBT.
- A study involving 79 adult patients revealed that those who received LTV had significantly lower rates of CMV reactivation compared to those who did not, with 11.1% versus 82.4% at day 100 and 45.3% versus 82.4% at one year.
- Despite the lower reactivation rates, approximately 34.2% of patients experienced late CMV reactivation after stopping LTV, suggesting the need for ongoing monitoring and potential extension of LTV use
Letermovir prophylaxis for cytomegalovirus is associated with risk of post-transplant lymphoproliferative disorders after haploidentical stem cell transplantation.
Haematologica
November 2024
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China; Peking-Tsinghua Center for Life Sciences, Beijing.
Not available.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!